Forty Seven

AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
MedCity News
AbbVie
I-Mab Biopharma
Forty Seven
lemzoparlimab
cancer immunotherapy
Flag link:
Gilead trumpets data with newly-bought magrolimab in blood cancers
Gilead trumpets data with newly-bought magrolimab in blood cancers
Pharmaforum
Gilead Sciences
ASCO 2020
Forty Seven
magrolimab
M&A
MDS
Flag link:
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Biopharma acquisitions slow, but it's not Covid-19's fault yet
EP Vantage
M&A
COVID-19
Gilead Sciences
Forty Seven
Eli Lilly
Dermira
Takeda
Hypera Pharma
ANI Pharmaceuticals
Amerigen Pharma
Flag link:
A Covid-19 threat to business acquisitions
A Covid-19 threat to business acquisitions
EP Vantage
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Flag link:
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Pharmaceutical Business Review
Forty Seven
Rocket Pharmaceuticals
R&D
Fanconi Anemia
pediatric
Flag link:
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Investors Business Daily
Gilead Scinecs
M&A
Forty Seven
immuno-oncology
Flag link:
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Fierce Biotech
Gilead Sciences
M&A
Forty Seven
CD-47
Flag link:
Gilead hungry for 'don't eat me' cancer biotech: reports
Gilead hungry for 'don't eat me' cancer biotech: reports
Fierce Biotech
Gilead Sciences
Forty Seven
cancer
M&A
Flag link:
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Yahoo/Benzinga
earnings
Forty Seven
Jounce Therapeutics
Catalyst Biosciences
Kodiak Sciences
Adverum Biotechnologies
IPOs
Beam Therapeutics
Flag link:
This Cancer Drug Is Driving Forty Seven's Stock Higher
This Cancer Drug Is Driving Forty Seven's Stock Higher
Motley Fool
Forty Seven
magrolimab
clinical trials
myelodysplastic syndrome
Flag link:
Forty Seven bucks the trend
Forty Seven bucks the trend
EP Vantage
Forty Seven
CD47
hematology
magrolimab
colorectal cancer
Flag link:
This Small-Cap Biotech Rose as Much as 98.3% Today
This Small-Cap Biotech Rose as Much as 98.3% Today
Motley Fool
Forty Seven
ASH2019
magrolimab
monoclonal antibodies
AML
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
Forty Seven and AstraZenca Team up on NHL Triple-Combination Therapy
BioSpace
AstraZeneca
Forty Seven
clinical trials
diffuse large B-cell lymphoma
Flag link:
It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M
It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M
Endpoints
biotech
IPOs
Tricida
Translate Bio
Forty Seven
Neon Therapeutics
Aquestive Therapeutics
Flag link:
The Biotech IPO Rush Continues With Four More Coming Soon
The Biotech IPO Rush Continues With Four More Coming Soon
CP Wire
biotech
IPOs
Neon Therapeutics
Forty Seven
Translate Bio
Tricida
Flag link:
The Biotech IPO Rush Continues With Four More Coming Soon
biotech
IPOs
Neon Therapeutics
Forty Seven
Translate Bio
Tricida
Flag link:
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven
Endpoints
Genentech
anti-PD-1 immunotherapy
Forty Seven
Flag link: